In the present study, we determined the antibody responses to the catalytic domain of wild-type BRAF and peptide P25 in Chinese patients with RA, primary Sjögren's syndrome (pSS), and systemic lupus erythematosus (SLE) by indirect enzyme-linked immunosorbent assays (ELISAs) and investigated the possible associations between these antibodies and the disease indicators of RA. This evidence concerns the gene BRAF and rheumatoid arthritis.